Solvias achieves total revenues of CHF 46 million in 2012(PresseBox) (Kaiseraugst, )
Despite the challenging market conditions, Solvias was able to record a slight increase in sales in 2012. This result reflects differing developments in the individual business units.
The Business Unit Analytical Services expanded its market position in Europe. In the US not only was Solvias able to maintain its strong position in the field of solid-state development, but also to sell analytics for small molecules and biopharmaceuticals. Over all this led to promising growth in sales, even in the face of increasing competition. The high demand for elemental and trace analysis, the increased need for stability studies as well as positive developments in biopharmaceuticals made an especially solid contribution to this growth.
Business Unit Synthesis & Catalysis faced with a difficult market environment, without improvement compared to the previous year. Continued pressure due to competitors from the Far East coupled with project delays, toxicological problems and funding difficulties for biotechs resulted in a decline in early-phase projects for Synthesis. On the other hand Solvias booked a slight increase in sales in 2012 with the catalysis and ligand technology platform and the ligand business performed very well.
Business Unit Process Analytical Technology had a very busy and successful financial year, with sales remaining at a high level. New developments and opportunities for using special technologies allow for additional applications to be realized in Process Analytical Technology. The demand for Chemical Hazards Monitors remains high.
Patenting and patent administration services were suspended mid-year due to a decline in both external demand and internal needs.
Solvias expects further growth in 2013. The order book looks promising. While pressure on prices will continue Solvias relies on mostly stable exchange rates for US dollars and Euro.
Due to the regained momentum for revenue growth, Solvias is in a position to repeal certain measures for cost reductions. The temporary increase in weekly working time to 42 hours will be decreased to 40 hours in mid-2013.
After the acquisition of the Confarma Group was concluded in January, one of the main tasks in 2013 will be to reshape the resulting Solvias Group. The expanded market presence with its optimized product portfolio, the utilization of synergies as well as the strengthened competitive position offer substantial potential for the future. This provides a solid basis for the projected revenue growth and a significant improvement in Solvias' earnings situation in the years to come. The ongoing expansion of its offerings in those areas with strong growth will also contribute to this development.
At the Solvias Annual General Meeting held yesterday, Mike Baronian, Luzi A. von Bidder (Chairman of the Board of Directors), Christian Leemann and Dr. Hansjörg Walther (Delegate of the Board of Directors and CEO) were re-elected to the Board of Directors. Dr. Karen Huebscher was newly elected to the Board of Directors.
As an unlisted company, Solvias does not publish profit figures.